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The assembly of the viral replicase complex (VRC) on subcellular membranes is a key step in the
replication process of plus-stranded RNA viruses. In this work, we have identiﬁed lethal and
temperature sensitive (ts) point mutations within the essential p33:p33/p92 interaction domain of
p33 and p92 replication proteins of Cucumber necrosis virus, a tombusvirus. Mutations within the
p33:p33/p92 interaction domain also affected viral RNA recombination in yeast model host. An in vitro
approach based on yeast cell free extract demonstrated that several p33 and p92 mutants behaved as
dominant-negative during VRC assembly, and they showed reduced binding to the viral (þ)RNA and
affected activation of the p92 RdRp protein, while they did not directly inﬂuence () or (þ)-strand
synthesis. Overall, the presented data provide direct evidence that the p33:p33/p92 interaction
domains in p33 and p92 are needed for the early stage of virus replication and also inﬂuence viral
recombination.
& 2012 Elsevier Inc. All rights reserved.Introduction
Positive-stranded (þ)RNA viruses infecting eukaryotic hosts
share many fundamental processes during their replication. The
similarities include (i) the participation of (þ)RNA in translation
to produce essential viral replication proteins as well as in
genome replication as a template; (ii) the use of ()RNA as
template for production of (þ)-strand RNA progeny in an asym-
metric manner; (iii) the need for virus-speciﬁc replicase com-
plexes (VRC), which are associated with intracellular membranes;
and (iv) the use of subverted host proteins to facilitate viral
replication (Bartenschlager et al., 2010; den Boon and Ahlquist,
2010; Miller and Krijnse-Locker, 2008; Nagy and Pogany, 2011;
Novoa et al., 2005; Salonen et al., 2005; Shi and Lai, 2005). Indeed,
all (þ)RNA viruses likely depend on or require host factors to
replicate their genomic RNAs in infected cells (Bartenschlager
et al., 2010; den Boon et al., 2010; Li and Nagy, 2011; Nagy and
Pogany, 2010, 2011, 2012; Nagy et al., 2011; Shi and Lai, 2005).
Due to the above similarities, our understanding of replication of
(þ)RNA viruses has advanced signiﬁcantly in the last decade
based on a small number of model viruses, includingll rights reserved.
t Pathology, University of
40546, USA.tombusviruses, such as Tomato bushy stunt virus (TBSV) and
Cucumber necrosis virus (CNV).
Similar to other (þ)RNA viruses, the genomic RNA of TBSV and
other tombusviruses is replicated by the membrane-bound VRC
(Nagy, 2008; Nagy and Pogany, 2010, 2011; White and Nagy,
2004). The tombusvirus VRC contains the viral-coded p33 and p92
replication proteins and host-coded proteins, including glyceralde-
hyde-3-phosphate dehydrogenase, the heat shock protein 70 chaper-
ones (Hsp70), pyruvate decarboxylase (Serva and Nagy, 2006),
Cdc34p E2 ubiquitin conjugating enzyme, Ded1 DEAD-box RNA
helicase, eukaryotic translation elongation factor 1A (eEF1A), eukar-
yotic translation elongation factor 1Bgamma (eEF1Bg), Pex19p shut-
tle protein and the Vps23p adapter ESCRT protein (Barajas et al.,
2009; Barajas and Nagy, 2010; Huang and Nagy, 2011; Kovalev et al.,
2012; Li et al., 2008, 2009, 2010; Nagy and Pogany, 2012; Pathak
et al., 2008; Sasvari et al., 2011; Serva and Nagy, 2006; Wang and
Nagy, 2008). The roles of several of these proteins in tombusvirus
replication have been studied in some detail (Nagy and Pogany, 2010;
Pogany et al., 2008; Wang and Nagy, 2008; Wang et al., 2009a, b). In
addition to the above protein components, the tombusviral VRC also
contains the viral plus-strand RNA, which likely serves as an
assembly platform for the proteins (Panaviene et al., 2005; Pathak
et al., 2012; Pogany et al., 2008). Due to the central role of the
assembly of the VRC in virus replication, detailed studies have been
conducted with several model RNA viruses to identify protein and
RNA factors affecting VRC assembly and to characterize interactions
Fig. 1. Mutations in p33:p33/p92 interaction domain in p33 replication co-factor inhibits TBSV repRNA replication in yeast. (A) Cartoons of p33 (1–296 aa) and p92 (1–818 aa,
a readthrough product of the p33 ORF, sharing the N-terminal 296aa with p33) replication proteins depicting various domains, such as S1 and S2 protein-protein interaction
subdomains, an RNA binding (RPR) and a transmembrane domains. The sequences of S1 subdomain (241–251 aa) and S2 subdomain (271–283 aa) are shown. Quick-change
mutagenesis approach was used to introduce speciﬁc mutations (seeMaterials and methods) into the S1/S2 subdomains. (B) Northern blot analysis of TBSV repRNA accumulation in
BY4741 yeast cells co-expressing one of the mutated CNV His6-tagged p33s, wt His6-p92 and DI-72 repRNA. The names of the S1/S2 subdomain mutants indicate the mutations
present in His6-p33. Yeast was grown at three different temperatures to identify temperature-sensitive mutants (shown in black ovals). Nonfunctional p33 mutants are boxed,
while the remaining mutants supported reduced repRNA accumulation. The control yeast expressed the wt His6-tagged p33, and the replication level was taken as 100%. The 18S
ribosomal RNA was used as a loading control (not shown). Quantiﬁcation was done with Imagequant software. The experiments were repeated 2 times.
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Nagy and Pogany, 2012).
The assembly of the tombusviral VRC likely starts with speciﬁc
interaction between the tombusviral (þ)RNA and the p33 and p92pol
proteins, which results in selection of the viral RNA for replication
and the recruitment of the viral RNA to the site of replication [i.e., the
cytoplasmic surface of the peroxisomal membrane (McCartney et al.,
2005; Panavas et al., 2005; Pathak et al., 2008)]. The speciﬁc binding
of p33 to the TBSV (þ)RNA requires the p33 recognition element
(p33RE), which includes a CC mismatch within a large, conserved
stem-loop structure, denoted RII(þ)-SL (Monkewich et al., 2005;
Pogany et al., 2005). p33 and the overlapping p92pol contains an
RNA-binding region (RPR domain, Fig. 1A) needed for binding to
p33RE of TBSV (þ)RNA (Pogany et al., 2005; Rajendran and Nagy,
2003). P33 and p92pol also contain two small p33:p33/p92 interac-
tion domains, denoted S1 and S2 (Fig. 1A), which are also required
for the speciﬁc recognition of p33RE in vitro (Rajendran and Nagy,
2004, 2006). The requirement for p33:p33/p92 interaction domain
for speciﬁc viral RNA binding indicates that p33 and p92pol likely
binds RNA as a dimer (or multimer). Because the N-terminal region
of p92pol has the same sequence as p33, it has been proposed that
p92pol might also be part of the above protein:RNA complex
(Rajendran and Nagy, 2004, 2006). In addition to binding to both
p92pol and to the TBSV (þ)RNA, p33 also binds to host factors, such
as Hsp70 (Nagy and Pogany, 2010), and it has peroxisomal targeting
sequences and membrane-spanning domains that facilitate the
association of p33 with peroxisomal membrane surfaces, the sites
of TBSV replication (McCartney et al., 2005; Panavas et al., 2005). In
spite of the above advances, our current understanding of the
assembly of TBSV VRC and the factors involved are incomplete.To further characterize the multifunctional nature of the p33
replication protein, in the ﬁrst part of the paper, we identify mutants
within the S1 and S2 subdomains of the p33:p33/p92 interaction
domain that render the replication protein nonfunctional, tempera-
ture sensitive (ts) or dominant-negative. Testing the accumulation of
TBSV RNA in yeast, a model host led to the identiﬁcation of critical
amino acid residues within the p33:p33/p92 interaction domain as
well as generation of ts mutants, which supported TBSV replication
only at the permissive temperature. Using temperature shift experi-
ments, we demonstrated that p33:p33/p92 interaction is required at
an early step in tombusvirus replication. Then, in the second part of
the paper, we dissect the mechanism of the inhibitory effect of p33/
p92 mutations on tombusvirus replication. We ﬁnd that mutations
within the p33:p33/p92 interaction domain reduced the efﬁciency of
the in vitro assembly of the functional tombusvirus VRC, affected the
in vitro activation of the p92 RdRp protein, and reduced the ability of
p33 to bind to the viral (þ)RNA. Altogether, the presented data
provide direct functional roles for the p33:p33/p92 interaction doma-
ins in p33 and p92 that are required for replication of tombusviruses.Results
Identiﬁcation of critical amino acid residues within p33:p33/p92
interaction domain of p33 replication protein affecting tombusvirus
replication in yeast
Previous works have deﬁned the S1 and S2 subdomains of the
p33:p33/p92 interaction sequence (Fig. 1A), which are known to be
essential for TBSV replication and the assembly of the tombusvirus
Table 1
The effect of mutations in the p33:p33/p92 interaction domain on p33 function.
Mutants Replication Recombination
In vivo In vitro In vivo
S1 subdomain
R241A Lethal o1%
L242V ts
L242F ts
LI242–243CT Lethal o5%
LI242–243SS Lethal
I243V ts Reduced Reduced
Y244A lethal
Y244F ts Reduced
Y244S Lethal o1%
Y244W Lethal
Q245A Lethal o1%
Q245F Lethal o1%
Q245N Reduced
R246A Lethal o1%
R246K Reduced Reduced
M248F ts Reduced Reduced
M248I Reduced
I249A Reduced Increased
E250A Lethal o1%
KDC254–256ASA Lethal
RY258–259AA Lethal
S2 subdomain
C272T ts o15% wt-like
C273F Lethal o5%
F274Y Reduced
F274W Reduced
F274A ts o5%
Y276F Reduced
Y276W Lethal
Y276A ts o5%
P277F ts o1% Reduced
D278A Reduced wt-like Reduced
D278F Reduced
PD277–278SS Reduced
G279A Reduced wt-like
V280A Reduced
E281A Reduced wt-like
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critical amino acid residues within the S1 and S2 subdomains for
tombusvirus replication, we introduced 34 site-speciﬁc mutations
into the p33 ORF in plasmid pGBK-His33, which expresses the p33
replication protein from the constitutive ADH1 promoter in yeast
(Panaviene et al., 2004). To launch TBSV replication in yeast model
host, we expressed the wt or mutated p33 together with p92pol
RdRp protein as well as the TBSV replicon (rep)RNA, termed DI-72,
as described earlier (Panavas and Nagy, 2003; Panaviene et al.,
2004). Northern blot analysis of total RNA preparations obtained
from yeast was used to estimate the accumulation level of TBSV
repRNA in yeast expressing either mutated or wt p33 (Fig. 1B).
To this end, we tested 19 S1 and 15 S2 subdomainmutants of p33
using different temperatures (23, 29 and 34 or 37 1C) to identify
possible temperature-sensitive (ts) mutants in this work (Table 1).
The list of p33 mutants included conservative and alanine mutants
carrying single or double point mutations. Interestingly, more than
half of the S1 subdomain mutants were replication incompetent (10
out of 19, Table 1) and 5 showed ts behavior in replication,
conﬁrming that this sequence is critical for tombusvirus replication
(Fig. 1B and Fig. 2) (Rajendran and Nagy, 2006). On the contrary, only
2 were replication incompetent and 4 ts mutants (out of 15, Table 1)
within the S2 subdomain, suggesting that this sequence is, albeit
playing a key role in replication, somewhat more tolerant to
mutations than the S1 sequence in tombusvirus replication.
The third group of p33 mutants supported TBSV repRNA
accumulation at all three temperatures tested (Fig. 2). Most ofthese mutants, however, showed reduced level of repRNA accu-
mulation when compared to the wt p33 in yeast, indicating that
changes of these amino acid residues were still detrimental for
tombusvirus replication. Altogether, the above experiments illu-
strated that the p33:p33/p92 interaction domain is critical for
TBSV repRNA replication in yeast, conﬁrming previous results
obtained with a small number of p33 and p92 mutants (Rajendran
and Nagy, 2004, 2006).Mutations within p33:p33/p92 interaction domain of p33 replication
protein affect tombusvirus recombination in yeast
To test if viral RNA recombination is affected by mutations
within the p33:p33/p92 interaction domain, we launched the
replication of DI-AU-FP repRNA, which supports recombination at
an increased rate when compared to DI-72 repRNA (Serviene
et al., 2006, 2005; Shapka and Nagy, 2004), in the presence of co-
expressed mutated p33 and wt p92pol replication proteins in
yeast. We performed the experiments at 23 and 34 1C to identify
ts mutants (Fig. 3). To this end, we identiﬁed 2 S1 and 2 S2
subdomain mutants (Fig. 3A and C) with decreased and 1 S1
mutant (I249A, Fig. 3A) showing increased level of RNA recombi-
nation (Table 1). Mutants I243V and M248F (Fig. 3B) did not
support recombination at detectable level at 34 1C after 48 h
incubation, suggesting that these mutants behave as ts mutants
not only for replication but for recombination as well. Altogether,
these data indicate that the p33:p33/p92 interaction domain is
also important in tombusviral RNA recombination.Use of ts mutant of p33 to deﬁne the early requirement
of p33:p33/p92 interaction for TBSV repRNA replication
Based on the ts nature of Y276A mutant of p33 (Table 1), we
used temperature shift experiments to test the effect of nonper-
missive temperature on TBSV repRNA replication. In the ﬁrst set
of experiments, we used the permissive temperature (20 1C) for 6,
8, 10, 12, and 14 h prior to shifting to the nonpermissive
temperature (34 1C) that continued up to 28 h total incubation
time (Fig. 4A). The data obtained suggested that tombusvirus
replication is especially dependent on p33:p33/p92 interaction
domain (i.e., on p33:p33 or p33:p92 interactions) within the ﬁrst
8 h, while it is less sensitive at latter time points.
In the second set of experiments, we used the nonpermissive
34 1C for 6, 8, 10, 12, and 14 h prior to downshift to the permissive
20 1C that continued up to 28 h total incubation time (Fig. 4B).
This experiment showed that tombusvirus replication could
‘‘recover’’ if the nonpermissive treatment only lasted for 6 h
(Fig. 4B, lanes 3–4). We observed only low level replication when
the nonpermissive treatment was longer than 6 h (Fig. 4B, lanes
5–12). Based on these data, we suggest that p33:p33 or p33:p92
interactions might be important at the beginning of tombusvirus
replication, possibly during the VRC assembly step. The relatively
efﬁcient replication when the nonpermissive treatment lasted
only for 6 h could be explained that the nonfunctional p33 mutant
expressed at 34 1C might rapidly become functional after the
downshift. Altogether, the interpretation of obtained data is
complicated by the nonsynchronized nature of tombusvirus
replication due to the continuous production of p33 and p92
proteins that can potentially assemble into functional VRCs even
at latter time points. Therefore, we needed to develop a more
synchronized in vitro assay to dissect the dependency of various
replication steps on p33:p33 and p33:p92 interactions (see
below).
Fig. 2. Identiﬁcation of ts mutants in p33:p33/p92 interaction domain in p33 replication co-factor in yeast. (A–C) Northern blot analysis of TBSV repRNA accumulation in
BY4741 yeast cells co-expressing one of the mutated CNV His6-tagged p33s, wt His6-p92 and DI-72 repRNA. See further details in Fig. 1B.
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p92 replication proteins based on a cell-free replication assay
To further characterize the functions of p33 and p92 proteins
in tombusvirus replication, we tested p33 mutants carrying
debilitating mutations within the p33:p33/p92 interaction region
in vitro (Table 1). The assay included a cell-free extract (CFE)
prepared from wt yeast (BY4741), which can support a single full
cycle of TBSV RNA replication, producing ()RNA and abundant
(þ)RNA progeny based on added (þ)repRNA template and
afﬁnity-puriﬁed recombinant MBP-tagged p33 and p92 from E.
coli (Pogany and Nagy, 2008; Pogany et al., 2008). We found that
p33 mutant C273F (CF) and Q245F (QF) reduced the level of TBSV
repRNA replication to 4% and 2%, respectively, close to the level
obtained with our negative control MBP (containing MBP-p92,
but missing MBP-p33 from the assay) (Fig. 5B, lanes 1–3).
Additional mutations in p33, such as I243V (IV) and C272T (CT)
reduced TBSV repRNA replication to 46 and 14%, respectively,
when compared to wild type (wt) levels (Fig. 5B, lanes 4, 5
versus 6, 7).
Altogether, we found that the 8 replication incompetent p33
mutants (based on the replication level in yeast) tested in the
CFE-based replication assay, all showed less than 5% activity
when compared with the wt p33 (Table 1). Among the 7 ts p33
mutants tested, we found more variations (between 1 and 50% ofwt level activity at 23 1C) in in vitro activities, while the 3 p33
mutants supporting reduced level of TBSV repRNA accumulation
in yeast, showed wt or close to wt level of activities in vitro
(Table 1). It is important to note that while there is only a single
cycle replication in the CFE-based replication assay, the yeast-
based assay support a number of sequential replication cycles,
where the progeny (þ)RNA from an early cycle becomes a new
template in a latter cycle. Thus, the differences in repRNA
accumulation in yeast among the various p33 mutants are
expected to be larger than in the CFE-based assay, where the
amount of the added template RNA is the same in each assay.
Nevertheless, the activity of the p33 mutants in the in vitro CFE-
based experiments correlates well with TBSV repRNA replication
levels observed in wt yeast cells (Table 1).
A similar approach based on CFE and p92 mutated within the
S1 and S2 subdomains in combination with wt p33 and TBSV
(þ)repRNA revealed that R241A (RA) and LI242–243CT (LT) muta-
tions within the p33:p33/p92 interaction region (Fig. 1A) caused
p92 to become nonfunctional (Fig. 5B, lanes 8 and 10), indicating
that this region is also critical for the p92 activity in vitro.
Interestingly, the same C273F (CF) mutation, which rendered p33
barely functional (4% activity, Fig. 5B, lane 1), only reduced the
activity of p92 by ﬁve-fold (Fig. 1B, lane 9). SDS-PAGE analysis
(Fig. 5B) showed that the different levels of activities were not
due to variations in the amounts of puriﬁed recombinant
Fig. 3. Identiﬁcation of mutants in p33:p33/p92 interaction domain in p33 replication co-factor that affects TBSV repRNA recombination in yeast. (A–C) Northern blot
analysis of accumulation of TBSV repRNA and recombinant (rec)RNAs in BY4741 yeast cells co-expressing one of the mutated CNV His6-tagged p33s, wt His6-p92 and DI-
AU-FP repRNA, which is highly recombinogenic. Yeast was grown at two different temperatures to identify temperature-sensitive mutants (shown in black ovals).
Nonfunctional p33 mutants are boxed, while the mutants that supported increased or reduced recRNA levels are indicated with arrows. The control yeast samples
expressed the wt His6-tagged p33. Note that we calculated the ratio of recRNA/repRNA in these studies. Quantiﬁcation was done with Imagequant software. The
experiments were repeated 2 times.
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interaction region are critical for the replication functions of p33
and p92 replication proteins and there is some difference
between p33 and p92, based on the different characteristic of
CF mutant when present in either p33 or p92.
Identiﬁcation of dominant-negative mutants of tombusvirus p33 and
p92 replication proteins based on a cell-free replication assay
Since the inactivity of the above p33 and p92 mutants could be
due to inefﬁcient formation of VRCs when the p33/p92 dimeriza-
tion/oligomerization is inhibited by the particular mutation
(Rajendran and Nagy, 2006), we wanted to complement the
mutant p33 replication protein with wt p33 in the CFE-based
replication assay. Therefore, to further characterize the deﬁciency
in the nonfunctional p33 mutants, we used mixtures of wt and
mutated replication proteins to program the CFE-based replica-
tion assay as shown in Fig. 6A. These experiments, however,
showed that the deﬁcient mutants of p33 interfered with the
normal replication functions of wt p33. For example, adding more
p33–Q245F mutant to the CFE assay containing constant amount
of wt p33 resulted in 93–97% inhibition of TBSV repRNA replica-
tion in the CFE assay (compare lanes 17–18 with 1, Fig. 6B).
Mutants I243V and C272T also inhibited TBSV repRNA replication
by 60–70% (Fig. 6B), while addition of puriﬁed MBP had no
inhibitory effect. In contrast, addition of more wt p33 or MBP did
not change repRNA replication (Fig. 6B, lanes 1–3 and 22–24),suggesting that the CFE is capable of supporting high level of
repRNA accumulation in the presence of high amount of recom-
binant proteins. Thus, the inhibitory role of p33–Q245F mutant is
unlikely due to nonspeciﬁc effect, such as the presence of too
much p33 protein in the CFE assay. Based on these observations,
we conclude that p33–Q245F mutant has a strong dominant-
negative function by interfering with TBSV repRNA replication.
To learn what stage of replication the dominant-negative
function of p33–Q245F mutant manifests, we performed a time-
course experiment using the CFE-based replication assay. The
tombusvirus replicase complexes assemble in 20–60 min in the
CFE (after mixing all of the required components), followed by
RNA synthesis up to 180 min (Pogany and Nagy, 2008; Pogany
et al., 2008). Addition of p33–Q245F mutant at the beginning of the
replication assay (0 time point, Fig. 6C, lane 8) had the largest
inhibitory effect by reducing TBSV repRNA level to 5% of the
control (when puriﬁed recombinant MBP was added to the assay,
Fig. 6C, lane 2). Moreover, addition of p33–Q245F mutant at the 10
and 20 min time point was still effective in inhibition of TBSV
repRNA accumulation in vitro (Fig. 6C, lanes 9–10), while its
inhibitory effect started to weaken when added at later time
points (60% inhibition when added at 40 and 60 min time
points, lanes 11–12, Fig. 6C). We observed a similar pattern for
inhibition of TBSV repRNA accumulation by another dominant-
negative mutant of p33 (DRPR that misses critical residues
required for RNA binding, Fig. 1A), which showed strong inhibi-
tory effect when added within the ﬁrst 20 min of the CFE assay
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had no signiﬁcant inhibitory effect at any time points (lanes 2–6,
Fig. 6C). Based on these ﬁndings, we conclude that the dominant-
negative p33 mutants (Q245F and DRPR) can interfere mostFig. 4. Temperature-shift experiments with ts p33 mutants indicate that the
function of the p33:p33/p92 interaction domain in p33 replication co-factor is
required in the early cycle of TBSV replication in yeast. (A and B) Northern blot
analysis of TBSV repRNA accumulation in BY4741 yeast cells co-expressing wt
His6-tagged p33 or p33-Y276A, wt His6-p92 and DI-72 repRNA. The time point for
the temperature shift is indicated. Note that all the yeasts were grown up to 28 h
before sampling. The control yeast expressed the wt His6-tagged p33 and was
grown at the given temperature (no temperature shift), and the replication level of
repRNA was taken as 100%. See further details in Fig. 1B.
Fig. 5. Mutations within the p33:p33/p92 interaction domain in p33 and p92pol repli
(A) A scheme of the CFE-based TBSV replication assay with added puriﬁed recombinan
(þ)repRNA. The whole cell extract (CFE) was prepared from yeast. The in vitro assays
newly synthesized 32P-labeled repRNA in an in vitro CFE-based replication assay using
indicated with an asterisk. The new full-length repRNA product is shown with arrow
(C) Bottom image: Coomassie blue staining of SDS-PAGE shows similar amounts of afﬁ
used in the above CFE replication assays.efﬁciently with TBSV repRNA replication during the early stages
of replication, likely the replicase assembly step. The remaining
inhibitory effect of these dominant-negative mutants at latter
time points could be due to the inhibition of still on-going
replicase complex assembly, which is not synchronized in this
assay and likely continues during the entire time of the 3 h-long
assay (Pogany and Nagy, 2008; Pogany et al., 2008). Alternatively,
the dominant-negative p33 mutants might directly inhibit the
RNA synthesis step (see below).
Similar CFE-based replication assay using wt p33 and wt p92
and increasing amounts of p92 mutants (Fig. 7A) revealed that
p92–LI242–243CT mutant showed a strong dominant negative
effect by reducing TBSV repRNA replication by 90% (Fig. 7B,
lanes 1–3 versus 4–6). Thus, similar to p33, the p33:p33/p92
interaction domain in p92 is likely critical for the assembly of the
tombusvirus VRC.Inhibition of the tombusvirus replicase by short peptides in a cell-free
replication assay
Several mutations within the p33:p33/p92 interaction subdo-
mains had dominant-negative effects, thus suggesting that inter-
action between the TBSV p33 and p92pol molecules is likely
critical for replicase activity in vitro. To further test if interruption
of the interaction between the tombusvirus p33 and p92pol
molecules interferes with the function of the VRC, we measured
the inhibitory effect of peptides on the in vitro activity of the
tombuvirus replicase based on the CFE assay. Interestingly, the
S1/S2 peptide representing the p33:p33/p92 interaction domain
inhibited the in vitro activity of the tombusvirus replicase by 3-
fold (Fig. 8B, lanes 3–4), while the RPR peptide representing the
RNA binding domain in p33/p92 also inhibited the activity by
more than 2-fold (lanes 5–6). On the contrary, the activity of
the unrelated Flock house virus (FHV) replicase was not inhibitedcation proteins inhibits RNA synthesis based on cell-free TBSV replication assay.
t p33 and p92pol replication proteins of TBSV and in vitro transcribed TBSV DI-72
contained ATP/CTP/GTP and 32P-UTP. (B) A representative denaturing PAGE gel of
puriﬁed recombinant wt or mutated p33 and p92 proteins. The mutated protein is
head. Experiments were repeated three times and quantiﬁed using Imagequant.
nity-puriﬁed recombinant MBP-p33 proteins (left panel) or MBP-p92 (right panel)
Fig. 6. Identiﬁcation of dominant-negative p33 mutants in vitro. (A) A scheme of the yeast CFE-based assay. (B) Increasing amounts of recombinant p33 mutants (2, 3 and
4 pmol) were added to the CFE-based replication assay simultaneously with wild type p33, p92, repRNA, and ribonucleotides. The new repRNA product is depicted with
arrowhead. Note that puriﬁed recombinant MBP and MBP-p33 were used as controls. (C) The maximum dominant-negative effect of the p33 mutants is exerted during
VRC assembly. The in vitro CFE-based replication assay was performed using p33-Q245F and p33-DRPR mutants as shown. We provided the recombinant proteins (3 pmol
of p33, 1 pmol of p92 and 3 pmol of mutants or MBP) at the 0, 10, 20, 40 or 60 min time points followed by continuation of the in vitro replication assay up to 2 h. The
denaturing PAGE analysis of the 32P-labeled repRNA products obtained is shown. RepRNA accumulation in yeast CFE lacking the mutant p33 has been chosen as 100%.
Fig. 7. Identiﬁcation of a dominant-negative p92 mutant in vitro. (A) A scheme of
the yeast CFE-based assay. (B) Increasing amounts of recombinant p92-LI242–243CT
mutant (1, 2, and 3 pmol) were added to the CFE-based replication assay
simultaneously with wild type p33 (3 pmol), wt p92 (1 pmol), repRNA (2.5 pmol),
and ribonucleotides. The new repRNA product is depicted with arrowhead. Note
that puriﬁed recombinant wt MBP-p92 was used as a control. See further details in
Fig. 6.
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the inhibitory effects of S1/S2 and RPR peptides on the tombus-
virus replicase are speciﬁc. Based on these data, we propose that
interaction between p33 and p92pol molecules are required for
the tombusvirus replicase activity, suggesting that p33 and p92pol
molecules functions as multimers in vitro.
Mutations within the p33:p33/p92 interaction region inhibit the
in vitro assembly of the tombusvirus replicase
To obtain more direct evidence that mutations within the
p33:p33/p92 interaction region interfere with the assembly of the
functional tombusvirus replicase complex, we performed an
in vitro replicase assembly assay based on the yeast CFE andpuriﬁed recombinant p33 and p92 proteins (Fig. 9A). For this
assay, we used only rATP and rGTP in the CFE assay, which
facilitate the assembly process (Pogany and Nagy, 2008; Pogany
et al., 2008), followed by solubilization and afﬁnity-puriﬁcation of
the assembled tombusvirus replicase (Pathak et al., 2012). Then,
the activity of the puriﬁed replicase preparations is compared by
using the TBSV-derived RI/III() as a template (Fig. 9B). Since
functional p33, p92 and (þ)repRNA is required for the in vitro
assembly and activation of the tombusvirus replicase (Pathak
et al., 2012; Pogany et al., 2008), this test is suitable to measure
how functional the various p33 and p92 mutants are in this
process. Accordingly, we found that p33-Q245F, p92-R241A and
p92-LI242–243CT were nonfunctional, while other mutants, such as
p33-C272T, p33-C273F and p92-C273F, were poorly functional in the
in vitro replicase assembly (Fig. 9B). As expected, p33-I243V
supported reduced, but signiﬁcant activity in this test (52% of
wt p33, Fig. 9B, lane 1). Altogether, these data conﬁrmed that the
p33:p33/p92 interaction region in p33 and p92 is critical during
the tombusvirus replicase assembly process.
The p33:p33/p92 interaction domain in p92 is critical for activation
of RdRp activity in vitro
In addition to the requirement for assembly of the membrane-
bound tombusvirus replicase complex, the RdRp subunit (i.e., p92)
has to be activated prior to complementary RNA synthesis
(Panaviene et al., 2004; Pathak et al., 2012; Pogany et al., 2008).
We have previously developed an in vitro assay that can perform
the activation of the tombusvirus RdRp in the presence of soluble
yeast factors (Pogany and Nagy, 2012). The activation is based on
an N-terminally truncated p92 RdRp protein, called p92-D167
(Fig. 10A), and does not require the membrane fraction of the
yeast CFE (Pogany and Nagy, 2012). The activated p92-D167 is
capable of producing a 30terminal extension product with the
TBSV (þ)repRNA template (Fig. 10B) (Pogany and Nagy, 2012).
Testing p92-D167 mutants carrying mutations in the S1 and
S2 subdomains in the in vitro RdRp activation assay revealed that
R241A and LI242–243CT mutations fully interfered with the activa-
tion of the in vitro RdRp activity (Fig. 10B, lanes 6 and 8), while
Fig. 8. Inhibition of tombusvirus replication by the S1/S2 peptide in the CFE-based
assay. (A) A scheme of the CFE-based replication assay. The yeast used for
preparation of CFE co-expressed the CNV p33 and p92 in the absence of the
repRNA, which prevents full assembly and activation of the replicase in the cells.
The in vitro assays contained the peptides, DI-72 (þ)RNA, ATP/CTP/GTP and 32P-
UTP. (B) Denaturing PAGE analysis of the 32P-labeled RNA products obtained in an
in vitro assay with the tombusvirus replicase based on CFE. The assay contained
0.5 mg/ml (ﬁnal concentration) of either S1/S2 (lanes 3–4) or RPR (lanes 5–6)
peptides. (E) Lack of inhibition of the in vitro activity of the FHV replicase by the
TBSV peptides in a CFE-based assay. Denaturing PAGE analysis of the 32P-labeled
RNA products shows the activity of the FHV replicase in the CFE assay containing
0.5 mg/ml (ﬁnal concentration) of S1/S2 (lanes 2–3) or 0.5 mg/ml RPR (lanes 4–5)
peptides. The positions of RNA1 and the subgenomic RNA3 are marked. Note that
the yeast used for CFE preparation expressed the FHV RNA1.
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strongly support the model that the S1 and S2 subdomains of p92
also participate in the activation of the p92 RdRp function.
Dominant-negative p33 mutants cannot inhibit the tombusvirus
replicase after the assembly step
To study the effect of the dominant-negative mutants on the
RNA synthesis steps only (without them affecting the VRC
assembly step), we performed in vitro tombusvirus replicase
assembly by using only two (i.e., rATP, rGTP) of the four ribonu-
cleotides in the CFE assay (Fig. 11A), which facilitate the assembly
process, but lead to an arrest of the replication process just after
repRNA recruitment and replicase complex assembly (Pogany and
Nagy, 2008; Pogany et al., 2008). These CFE-based replicationassays consisted of wt p33 and wt p92 proteins (Fig. 11B and C,
lanes 1–4) or p33 mutants (Fig. 11B, lanes 5–10) and p92 mutants
(Fig. 11C, lanes 5–10). After removal of the supernatant (including
all the viral and cellular proteins and repRNA template not bound
to the membrane), we added the wt or mutated p33 and p92 to
the CFE in addition to the four rNTPs to promote repRNA
replication during the second step of the assay (Fig. 11A). We
found that the addition of wt p33 at the second step improved the
activity of the tombusvirus replicase only marginally from 39% to
47% in case of p33-I243V (lane 5 versus 8 in Fig. 11B) and 10–17%
in combination with p33-C272T (lane 7 versus 10 in Fig. 11B), but
did not complement the inactive p33-Q245F mutant (lanes 6
versus 9, Fig. 11B). Based on these data, we suggest that the wt
p33 cannot complement or only poorly complement the p33
mutants after the assembly of the tombusvirus replicase in vitro.
We also tested the reverse scenario for dominant-negative
effect of the p33 mutants. Here, the wt p33 and wt p92 were used
during the ﬁrst step to assemble the tombusvirus replicase,
followed by addition of the mutated p33 during the second step.
Interestingly, the strong dominant-negative p33-Q245F mutant or
the other p33 mutants could not affect the activity of the
tombusvirus replicase pre-assembled with wt p33 and wt p92
(compare lanes 1 to 2–4 in Fig. 11B).
We also performed similar experiments with p92 mutants
(Fig. 11C). These experiments revealed that the tombusvirus
replicase pre-assembled during the ﬁrst step was not affected
by addition of wt or mutated p92 during the second step
(compare lanes 5–7 versus 8–10 in Fig. 11C). Also, similar to
p33, the low activity of replication complexes assembled by
mutated p92 mutants could not be rescued by wt p92 when
provided after the assembly process.
In addition to the fraction of p33/p92 and repRNA, which were
not bound to the membrane, the supernatant has also been
removed at the end of the ﬁrst step to prevent additional replicase
assembly during the second step (Fig. 9A). Therefore, it is possible
that the added replication proteins during the second step of the
assay (Fig. 9A) could not associate with the membrane due to the
absence of soluble host factors. This is because for the proper
membrane insertion and function, tombusvirus replication pro-
teins depend on host factors (i.e., Hsp70 chaperone and eEF1A) (Li
et al., 2009, 2010; Sasvari et al., 2011; Wang et al., 2009a, b),
which are provided in the supernatant of the CFE. Therefore, we
also performed experiments in which we provided the CFE
supernatant fraction together with wt or mutated p33 to the
tombusvirus replicase during the second step (Fig. 11D). The
mutant p33 proteins, when added to the pre-assembled replicase
with wt p33/wt p92 (Fig. 11E lanes 1–3), could not inhibit repRNA
replication in case of p33-Q245F and p33-C272T, and only slightly
in case of the dominant-negative p33-DRPR mutant. Also, the
minimal level of repRNA replication supported by the p33
mutants was not complemented using the CFE supernatant in
combination with wt p33 (Fig. 11E, lanes 4–6). Altogether, these
results suggest that the tombusvirus replicase complexes pre-
assembled using mutant replication proteins are permanently
deranged beyond the capability of wt proteins to rescue func-
tional replicases. Alternatively, the pre-assembled tombusvirus
replicases consist of membrane-bound structures too closed to
allow the entry of wt MBP-p33 (75 kDa) or MBP-p92 (134 kDa).
Dominant-negative p33 and p92 mutants do not inhibit the RNA
synthesis by the puriﬁed tombusvirus replicase or carmovirus RdRp
in vitro
To test further if the dominant-negative mutants could inhibit
RNA synthesis step, we used puriﬁed tombusvirus replicase
preparation obtained from yeast (Panaviene et al., 2004, 2005).
Fig. 9. Mutations within the p33:p33/p92 interaction domain in p33 and p92pol replication proteins inhibits the in vitro assembly of the CNV replicase complex.
(A) A scheme of the CFE-based replicase assembly assay with added puriﬁed recombinant p33 and p92pol replication proteins and in vitro transcribed (þ)repRNA. The
whole cell extract (CFE) was prepared from yeast. After the in vitro assembly, which was performed in the presence of ATP and GTP, the membrane-bound viral replication
complexes were puriﬁed by afﬁnity chromatography and then the replicase activity was tested using RI/RIII(-) template. The in vitro assays contained ATP/CTP/GTP and
32P-UTP. Note that the DI-72(þ) repRNA serves only as an assembly factor in this assay since this repRNA is lost during solubilization of the membrane and afﬁnity
puriﬁcation of the replicase (not shown). (B) Denaturing PAGE analysis of the replicase assay with RI/RIII(-) template. The full-length RNA product is depicted with an
arrowhead. All the samples contained comparable amounts of wt or mutated p33 replication protein or wt or mutated p92 replication protein. The mutated protein is
indicated with an asterisk.
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which is solubilized and puriﬁed that leads to the loss of the
endogenous RNA template, and it can be programmed with added
TBSV RNA (Panaviene et al., 2004, 2005). We found that the
addition of the puriﬁed recombinant p33 and p92 mutants did not
inhibit the plus-strand synthesis activity of the tombusvirus
replicase programmed with RI/RIII() RNA template [derived
from DI-72 ()RNA (Panavas et al., 2002)] (Fig. 12A). Similarly,
the addition of the puriﬁed recombinant p33 and p92 mutants did
not inhibit the plus-strand synthesis activity of the puriﬁed TCV
RdRp programmed with RI/RIII() RNA template, which is used
by the TCV RdRp efﬁciently (Rajendran et al., 2002) (Fig. 12B).
Based on these in vitro data, we conclude that p33 and p92
mutants cannot inhibit plus-strand synthesis.
Dominant-negative p33 mutants show reduced RNA-binding in vitro
Although the dominant-negative p33 mutants tested in this
work have mutations within the p33:p33/p92 interaction region
(Fig. 1A), it is possible that these mutations might have altered
the RNA-binding capacity of the p33 protein as well. This was
tested by using EMSA with two TBSV RNA probes. The wt RNA
probe contained a short region [RII(þ)-SL) involved in selective
binding to p33, while the mutated RNA [RII(þ)-SL:G/C] carried a
debilitating G-to-C mutation, which interferes with binding to
p33 (Monkewich et al., 2005; Pogany et al., 2005). We found that,
unlike the wt p33 [we used the wt sequence representing the
soluble portion of p33, called p33C (Pogany et al., 2005;
Rajendran and Nagy, 2003)] (compare lanes 5–8 with 1–4,
Fig. 13A) and p33-C272T (Fig. 13B, lanes 7–9) that bound selec-
tively to the wt RNA probe, the p33-Q245F mutant bound to
neither RNA probes (Fig. 13A, lanes 9–16). While p33-I243V bound
inefﬁciently to the wt RNA probe (lanes 21–24, Fig. 13A), but not
to the mutated probe (lanes 17–20). These ﬁndings suggest that
the p33:p33/p92 interaction region is involved in binding of p33
to the viral RNA.Discussion
Replication of (þ)-strand RNA viruses is performed by viral
replicases assembled from viral and co-opted host-coded compo-
nents on subverted subcellular membrane surfaces. These viruses
only code for a small number of replication proteins, which then
perform a surprisingly large number of functions in infected cells
(Nagy et al., 2012; Nagy and Pogany, 2012). The tombusvirus p33
replication protein is such factor that provides an increasing
number of functions during replication. Accordingly, p33 is
regarded as a master regulator of tombusvirus replication that
is involved in selective binding to the tombusvirus (þ)RNA, and
recruitment of the viral RNA into replication (Monkewich et al.,
2005; Pathak et al., 2012; Pogany et al., 2005). p33 is also
component of the viral replicase complex and affects VRC assem-
bly and regulates viral RNA synthesis by acting as an RNA
chaperone (Panaviene et al., 2004, 2005; Pogany and Nagy,
2008; Pogany et al., 2008; Stork et al., 2011). p33 also interacts
with a large number of host proteins that is needed for co-opting
host proteins and altering cellular pathways (Li et al., 2008;
Mendu et al., 2010; Nagy, 2008; Nagy and Pogany, 2010, 2012).
To perform so many different functions, p33 contains multiple
functional domains (Fig. 1A) (Nagy and Pogany, 2008; Stork et al.,
2011). The C-terminal p33:p33/p92 interaction domain, consist-
ing of the S1 and S2 subdomains, is critical for tombusvirus
replication, subcellular localization of VRC and the selective
binding to the viral (þ)RNA (Panavas et al., 2005; Pogany et al.,
2005; Rajendran and Nagy, 2006). We ﬁnd that changing con-
served amino acids within the S1 and S2 subdomains has
frequently led to substantial effect on p33 functions, resulting in
lethal (nonfunctional), ts and dominant-negative features during
replication in yeast model host (Table 1). Interestingly, mutations
within the S1 subdomain were more frequently detrimental to
p33 functions then mutations within the S2 subdomain, albeit
both subdomains are critical for tombusvirus replication (Table 1)
(Rajendran and Nagy, 2004, 2006). We also show that several
Fig. 10. The p33:p33/p92 interaction domain is required for the RdRp activity of the N-terminally truncated p92pol replication protein in the cell-free yeast extract.
(A) Schematic representation of the N-terminally truncated p92pol replication protein, termed D167, and the location of known functional domains in the wt p92. The
N-terminal segment in the CNV p92pol contains the same sequence as in p33 due to the overlapping expression strategy of the CNV genome. The various domains in the
shared sequences are termed as: ub, monoubiquitinated sequence; mPTS, peroxisomal membrane targeting sequences; TMD, trans-membrane domain; late domain,
whose sequence is recognized by the host ESCRT factors; P, phosphorylation sites; RPR, arginine-proline-rich RNA-binding domain; S1 and S2 are subdomains of the
p33:p33/p92 interaction domain. The C-terminal region of p92pol carries the RdRp domain and two RNA-binding sequences. (B) Top image: denaturing PAGE analysis of
the 32P-labeled RNA products obtained in an in vitro assay with recombinant CNV proteins (the wt p33 and p92 are shown here as C33 and C92, while the N-terminally
truncated p92pol replication protein is D167). The results with the CNV p92-D167 mutants with mutations within the p33:p33/p92 interaction domain is shown in lanes
6–8 (1 pmol). The 30-TEX (terminal extension) products produced by the CNV p92-D167 RdRp are pointed at with an open arrowhead, while the de novo products
(supported in the presence of C33) were depicted with black arrowhead. Each experiment was repeated two or three times. Note that we used the previously characterized
TBSV p92-D167 RdRp as a control. Bottom image: Coomassie blue staining of SDS-PAGE shows similar amounts of afﬁnity-puriﬁed recombinant wt or mutated MBP-D167
RdRp proteins used in the above CFE replication assays.
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repRNA recombination in yeast, supporting that the interaction
domain is involved in regulation of template-switching events,
the major pathway for RNA recombination in tombusviruses
(Cheng and Nagy, 2003; Jaag et al., 2010; Nagy, 2011).
Many mutants within the S1 and S2 subdomains have been
shown to affect p33:p33 and p33:p92 interactions (Rajendran and
Nagy, 2004, 2006), suggesting that the detrimental effects of these
mutations on tombusvirus replication are due to the reduced level
of interaction between p33 and p33 as well as p33 and p92. The
critical role for the p33:p33 and p33:p92 interactions are also
supported by the inhibitory effect of the S1/S2 peptide on the
activity of tombusvirus replicase (Fig. 8). But what is the functional
role(s) of the p33:p33 and p33:p92 interactions during replication?
Detailed in vitro characterization of selected S1 and S2 sub-
domain mutants revealed that these subdomains are directly
involved in critical functions, such as: (i) binding to the viral
(þ)RNA (Fig. 13); (ii) assembly of the functional VRC (Fig. 9); and
(iii) activation of the p92 RdRp (Fig. 10), while they are not
directly affecting () or (þ)-strand synthesis, based on experi-
ments using the CFE replication assay (Fig. 11) or data obtained
with the puriﬁed tombusvirus replicase (Fig. 12). These ﬁndings
are further supported by replication data from yeast based on ts
p33 mutants, which unraveled an early function for the S1 and S2subdomains in tombusvirus replication. The yeast data did not
support a major role for the S1 and S2 subdomains in the late
steps of tombusvirus replication, which include () or (þ)-strand
synthesis and the release of new (þ)RNA progeny from the site of
replication.
An unusual feature of tombusviruses is the overlapping
sequence shared by p33 and N-terminal portion of the p92
protein, which includes the S1 and S2 subdomains (Fig. 1A)
(White and Nagy, 2004). This overlaps makes it more challenging
to dissect the actual functions of S1 and S2 subdomains when
present in either p33 or p92 proteins. Mutations in S1 and S2
subdomains in both proteins, however, deﬁned that these regions
are critical for the functions of both p33 and p92 proteins (Fig. 5)
[see also Ref. (Panavas et al., 2005; Rajendran and Nagy, 2006) for
replication data from yeast]. This conclusion is further supported
by the identiﬁcation of dominant-negative mutants within the S1
subdomain of p33 and p92 (Figs. 6 and 7), indicating that
improper interactions between the dominant-negative mutant
and wt replication proteins could interrupt the normal replication
functions of the wt replication proteins. Surprisingly, mutations
within the p33:p33/p92 interaction domain also inhibited the
in vitro activity of a truncated p92 RdRp, suggesting that activa-
tion of the viral RdRp likely requires interaction between two or
more p92 RdRp proteins.
Fig. 11. Lack of complementation or dominant-negative effects of p33 and p92
mutants after the assembly of the tombusvirus VRC based on step-wise cell-free
replication assay. (A) Scheme of the CFE-based tombusvirus VRC assembly and
replication assays. Puriﬁed recombinant wt or mutated p33 (3 pmol, each) and
p92pol replication proteins of CNV (1 pmol) and in vitro transcribed TBSV DI-72
(þ)repRNA were added in step 1 to the CFE. The assay was performed with or
without the puriﬁed recombinant mutated p33 or p92 during step 1. Note that the
assay was performed in the presence of ATP/GTP to facilitate CNV VRC assembly, but
inhibit the RNA synthesis in step 1. After ﬁnishing step 1, the samples were centrifuged
to collect the membrane fraction of the CFE. This was then followed by washing the
membranes, and performing step 2 in the presence of ATP/CTP/GTP and 32P-UTP to
allow repRNA replication. Note that we also added the puriﬁed recombinant mutated
p33 or p92 at the beginning of step 2 as shown. (B) Denaturing PAGE analysis of the
32P-labeled repRNA products obtained in the CFE assays in the presence of the shown
puriﬁed recombinant wt or mutated MBP-p33 and wt MBP-p92. Each experiment was
repeated at least three times and the data were used to calculate standard deviation.
(C) Denaturing PAGE analysis of the 32P-labeled repRNA products obtained in the CFE
assays in the presence of the shown puriﬁed recombinant wt or mutatedMBP-p92 and
wt MBP-p33. See further details in panel B. (D) Modiﬁed scheme of the CFE-based
tombusvirus VRC assembly and replication assays. Note that these experiments are
similar to those described in panel A, except we added fresh supernatant of the yeast
CFE with puriﬁed recombinant wt or mutated p33 (3 pmol, each) and wt p92pol
(1 pmol) replication proteins of CNV at the beginning of step 2 as shown.
(E) Denaturing PAGE analysis of the 32P-labeled repRNA products obtained in the
CFE assays (see panel D) in the presence of the shown puriﬁed recombinant wt or
mutated MBP-p33 and wt MBP-p92. Note that the addition of the CFE supernatant
(containing soluble host factors) obtained after centrifuging yeast extract at 35,000 g
served to help membrane insertion of the added wt p33 (lanes 4–6) or the p33
mutants (lanes 1–3). See further details in panel B.
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p33:p33/p92 interaction domains in p33 and p92 replication
proteins affect several functions that are needed for the early
stage of virus replication and also inﬂuence viral recombination. It
is possible that many p33 and p92 molecules form large com-
plexes via the p33:p33/p92 interaction domains in infected cells
that facilitate protein localization, VRC assembly, and the activa-
tion of the viral RdRp. The possible role of the S1 and S2
subdomains in binding and interaction with host factors is
currently under investigation.Materials and methods
Yeast, Plasmids, Reagents and Antibodies
Saccharomyces cerevisiae strain BY4741a (MATa his3D1 leu2D0
met15D0 ura3D0) was used for this work. Plasmids expressing
His6-tagged p33 (pGBK-His33), p92 (pGAD-His92), p33 point
mutants Y244A, R246A, F274A, Y276A as well as pYC-DI-72 expres-
sing transcript RNA were described earlier (Panavas and Nagy,
2003; Panaviene et al., 2004; Rajendran and Nagy, 2004, 2006).
Also, pMAL-TCV-88c and pMAL-CNVDRPR were described earlier
(Rajendran and Nagy, 2003; Rajendran et al., 2002).
For obtaining pMAL-CNV-33, the CNV p33 ORF was ampliﬁed
using primers #25 (GGAGTCTAGAGATACCATCAAGAGGATG)/
#992B (GAGCTGCAGCTATTTCACACCAAGGGA) appended with
XbaI and PstI restriction enzymes to facilitate directional cloning
into pMAL-C2 vector (NEB) digested with the same pair of
enzymes. This expression results in a recombinant protein with
N-terminal Maltose Binding Protein (MBP) fusion. Same strategy
was used to clone the various S1 and S2 mutants. To generate
pMAL-CNV-92, the CNV p92 ORF was fused with MBP using the
same strategy as above except for changing the reverse primer to
#26 (GGAGCTGCAGTCATGCTACGGCGGAGTC). The same set of
primers was used to clone the various p92 mutants.
Primers #633 (CGACGGATCCATGTACGCTACCCTACCCAGGGA)/
#992B carrying BamHI and PstI sites were used for PCR to clone
the C-terminal half of p33 ORF that resulted in pMAL-CNV-33C.
The p33C mutants were fused with MBP in gel shift experiments.
To obtain pET-HisMBP-CNV33, we PCR-ampliﬁed the MBP-p33
ORF with primers #889 (GGAGCCATGGCTAAAATCGAAGAAGG-
TAAAC)/ #1403 (GCCGCTCGAGCTATTTCACACCAAGGGACTCA)
using pMAL-CNV-33 template. The PCR product was then cloned
into NcoI/XhoI digested pET vector resulting in a dually His6-MBP-
tagged p33 or p33 mutants. Similar strategy was used to obtain
pET-HisMBP-CNV92 and its His6-MBP-tagged mutants in pET
vector except from changing the reverse primer to #952
(CCCGCTCGAGTCATGCTACGGCGGAGTCAAGGA).
To generate pMAL-D167CNV-92, which expresses the CNV D167
RdRp lacking the N-terminal 167 aa, we used primers #4914
(CCAGGGATCCGCCCGAGCACATATGGAGGATG)/ #870 (CCCGTCTA-
GATTTGTGTTTGCTTGGTCATGCTACGGCGGAGTC) appended with
BamHI and XbaI for PCR. The obtained PCR product was cloned into
pMAL digested with the same pair of enzymes. Same primers were
used to clone the S1/S2 mutants of CNV D167 RdRp.
Site directed mutagenesis
Plasmids expressing mutant p33 and p92 were created using
Quick Change Mutagenesis Kit (Stratagene) with pGBK-His33 or
pGAD-His92 as template DNAs (Rajendran and Nagy, 2006). The
PCR reactions included the Pfu Turbo DNA polymerase, different
sets of primer pairs designed for each mutant and 40 ng of DNA
as a template. PCR products were digested with DpnI before
Fig. 12. Mutants within the p33:p33/p92 interaction domain in p33 or p92 does not have dominant-negative effect on the plus-strand synthesis activity of the afﬁnity-puriﬁed
tombusvirus replicase. (A) Representative denaturing gel of 32P-labeled RNA products synthesized by the puriﬁed CNV replicase in vitro in the presence of 2 or 4 pmol of
puriﬁed recombinant p33 and p92 mutants is shown. The level of complementary RNA synthesis producing ‘‘repRNA’’ (marked as ‘‘ti’’, the full-length product, made via de novo
initiation from the 30-terminal promoter) in each sample was compared to that of the replicase activity obtained with the recombinant MBP protein (lane 21–22). Note that this
replicase preparation also synthesizes internal initiation products (‘‘ii’’). The in vitro assays contained the DI-72 (-)repRNA, the afﬁnity-puriﬁed recombinant p33 or p92 mutants
in addition to ATP/CTP/GTP and 32P-UTP. Yeast co-expressing p33 and p92pol replication proteins and DI-72 (þ)repRNA was used to afﬁnity-purify the RNA-free CNV replicase.
Each experiment was repeated two times. (B) Representative denaturing gel of 32P-labeled RNA products synthesized by the puriﬁed TCV RdRp in vitro in the presence of 2 or
4 pmol of puriﬁed recombinant p33 and p92 mutants is shown. The TCV RdRp protein (named p88C) was puriﬁed from E. coli.
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mutations was conﬁrmed by sequencing.
RepRNA accumulation and recombination in yeast
The yeast-based replication and recombination experiments
have been performed as described previously (Shapka and Nagy,
2004; Shapka et al., 2005). RNA accumulation was done with
Northern blotting and speciﬁc probes (Shapka and Nagy, 2004;
Shapka et al., 2005).
Protein puriﬁcation from E. coli
The MBP-tagged CNV p33, CNV MBP-p92, or the p33/p92
mutants and TCV p88C were puriﬁed from E. coli as described
previously (Rajendran and Nagy, 2003; Rajendran et al., 2002).
Brieﬂy, expression of the MBP tagged proteins was induced by
isopropyl-d-thiogalactopyranoside (IPTG) in Epicurion BL21-
codon-plus (DE3)-RIL cells (Stratagene). Cells were suspended in
the column buffer (10 mM Tris–HCl [pH 7.4], 1 mM EDTA, 25 mM
NaCl, 10 mM b-mercaptoethanol) and were broken by sonication.
The cell lysate then was passed through the equilibrated amylose
columns to bind MBP tagged proteins. After passing the cell
lysate, the columns were washed three times with ice-cold
column buffer and eluted with column buffer containing 10 mM
maltose and stored at 80 1C until further use.
Cell free extract (CFE)-based in vitro replication assay
The CFE was prepared from untransformed yeast strain
BY4741 as described (Pogany and Nagy, 2008; Pogany et al.,
2008). Brieﬂy, the CFE (1 ml) was pre-incubated on ice for 10 min
in 10 ml cell-free replication buffer containing 0.2 M sorbitol,
50 mM HEPES-KOH, pH 7.4, 5 mM magnesium acetate, 150 mM
potassium acetate, and 0.4 ml actinomycin D (5 mg/ml). Then, the
reaction volume was adjusted to 20 ml using 1x cell-free replica-
tion buffer, also containing 2 ml of 150 mM creatine phosphate;
2 ml of 10 mM ATP, CTP, and GTP and 0.25 mM UTP; 0.3 ml of
[32P]UTP, 0.2 ml of 10-mg/ml creatine kinase, 0.2 ml of RNaseinhibitor, 0.2 ml of 1 M dithiothreitol, and 0.5 mg RNA transcript.
The reaction mixture also contained 4 pmol MBP-tagged CNV p33
and 1 pmol CNV MBP-p92 puriﬁed from E. coli cells (Rajendran
and Nagy, 2003; Rajendran et al., 2002). The CFE-based replica-
tion assay was performed at 25 1C for 3 h. The reactions were
terminated by adding 110 ml stop buffer (1% sodium dodecyl
sulfate [SDS] and 0.05 M EDTA, pH 8.0), followed by phenol–
chloroform extraction, isopropanol–ammonium actetate precipi-
tation, and a washing step with 70% ethanol as described earlier.
The RNA samples were electrophoresed under denaturing condi-
tions (5% PAGE containing 8 M urea) and analyzed by phosphoi-
maging using a Typhoon (GE) instrument as described (Panaviene
et al., 2005).Puriﬁcation of the recombinant tombusvirus replicase from yeast
Yeast cells (BY4741) transformed with pGBK-His33, pGAD-
His92 and pYC-DI72 were pre-grown in SC-ULH- medium con-
taining 2% glucose for 15 h at 29 1C with shaking at 250 rpm. The
afﬁnity-puriﬁcation of the solubilized tombusvirus replicase was
performed using ProBond resin (Invitrogen) as described
(Panaviene et al., 2004, 2005). The obtained template-dependent
CNV replicase was then used in a standard replicase assay using
either DI-72(-) or RI/RIII(-) exogenous templates and [32P]UTP
(Panaviene et al., 2004, 2005).In vitro assembly and puriﬁcation of CNV replicase complex
The in vitro replicase assembly assay was conducted at 20 1C
for 1 h as described (Kovalev et al., 2012). The reaction volume
was increased to 200 ml, while the ﬁnal concentration of DTT was
reduced from 10 mM to 2.5 mM. In addition, only rATP and rGTP
were used, while [32P]UTP was omitted. The recombinant p33
was dually-tagged with both MBP and 6xHis. After incubation, the
assay mixture was diluted with 800 ml chilled solubilization
buffer and afﬁnity-puriﬁcation was done exactly as described
(Panaviene et al., 2004, 2005).
Fig. 13. Mutants within the p33:p33/p92 interaction domain show reduced RNA binding in vitro. (A) Top image: EMSA was performed with 2, 4, 8 or 16 pmol of puriﬁed
MBP-tagged wt or mutant p33C (carrying 150–296 aa). The 32P-labeled RNA probes included 10 nM of wt RII(þ)SL RNA (a highly speciﬁc RNA binding site for p33C) or
10 nM of a mutated RNA [carrying C-G mutation within the CC mismatch of RII(þ)SL RNA]. Arrows depict the bound and unbound RNA probes. Note that p33-Q245F
mutant showed inefﬁcient viral RNA binding. Bottom image: SDS-PAGE followed by Coomassie blue staining of the puriﬁed recombinant proteins used in panel A.
(B) EMSA assay with puriﬁed recombinant p33-C272T mutant, similar to that shown in panel A.
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We used afﬁnity-puriﬁed recombinant TCV p88C (Rajendran
et al., 2002). Brieﬂy, the RdRp reaction was performed in 100 ml
volume containing RdRp buffer 40 mM Tris pH 8.0, 10 mM MgCl2,
10 mM DTT, 0.2 ml RNase inhibitor, 1 mM ATP, CTP, GTP, 0.1 ml
radioactive [32P]UTP and 50 ml RdRp preparation. As an external
template, 300 ng of DI-72(-) RNA or RI/III(-) RNA were added.
Samples were incubated at 25 1C for 2 h. The reaction was
terminated by adding 70 ml SDS/EDTA (1% SDS, 50 mM EDTA pH
8.0) and 100 ml phenol–chloroform (1:1). The analysis of RdRp
products was by nondenaturing PAGE (Rajendran et al., 2002).EMSA assay
The afﬁnity-puriﬁed recombinant proteins (1 mg as the highest
amount and twofold dilution series) were incubated with 1 ng of
radioactively labeled probe (see above) in a binding buffer (50 mM
Tris–HCl [pH 8.2], 10 mM MgCl2, 10 mM dithiothreitol, 10% gly-
cerol, 100 ng of yeast tRNA [Sigma], and 2 U of RNase inhibitor
[Ambion]) at 25 1C for 15 min (Pogany et al., 2005; Rajendran and
Nagy, 2003). After the binding reaction, the samples were analyzed
by 4 or 5% nondenaturing PAGE in Tris-acetate-EDTA buffer at200 V in a cold room. The gels were dried, exposed, and analyzed in
a phosphorimager.
Replication assay based on CFE
The CFE was prepared from BY4741 yeast co-expressing CNV
p33 and p92. The CFE-based replication assay was done according
to (Pogany and Nagy, 2008; Pogany et al., 2008), except the pre-
incubation step was omitted. Instead, the complete reaction was
incubated on ice for 5 min before switching the incubation to the
reaction temperature, usually room temperature. The reaction
buffer contained 50 mM potassium acetate instead of the
150 mM. The S1/S2 peptide (RLIYQRVMIEIMDKDCVRYVDRDVIL-
PLAIGCCFVYPDGVEES) and the RPR peptide (TKVIASTGRPRRR-
PYAAKIAQ) were synthesized by Peptide2.0. These peptides
were dissolved in the RdRp buffer (10 mg/ml ﬁnal concentration).
The peptides were added at the beginning of the replication
assays to reach 0.5 mg/ml ﬁnal concentration.
FHV replication assay
To obtain the FHV replicase preparation based on yeast CFE,
BY4741 yeast strain was transformed with plasmid pESC-His-
GAL1:FHV RNA1 (Kovalev et al., 2012). The preparation of CFE
K.B. Pathak et al. / Virology 437 (2013) 48–61 61was performed as described (Kovalev et al., 2012). The S1/S2 and
RPR peptides were applied in the FHV replicase assay as
described above.Acknowledgments
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